Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
NET REVENUE
Clinical testing revenue	$ 54,622	$ 22,839
BioPharma & research revenue	5,082	187
Total Revenue, net	59,704	23,026
COST OF REVENUE	32,531	13,482
GROSS MARGIN	27,173	9,544
Operating expenses:
General and administrative	18,005	6,522
Research and development	1,446	669
Sales and marketing	5,800	2,914
Total Operating Expenses	25,251	10,105
INCOME (LOSS) FROM OPERATIONS	1,922	(561)
Interest expense, net	1,593	195
Income (loss) before taxes	329	(756)
Income tax expense	174	5
NET INCOME (LOSS)	155	(761)
Deemed dividends on preferred stock	1,840
Amortization of preferred stock beneficial conversion feature	3,727
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (5,412)	$ (761)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.07)	$ (0.01)
Diluted	$ (0.07)	$ (0.01)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	76,068	60,277
Diluted	76,068	60,277